Education
About Us
Working with TipRanks
Follow Us
Synergy CHC (SNYR)
NASDAQ:SNYR
Top Page
Synergy CHC
(NASDAQ:SNYR)
Select Model
Select Model
Rating:47Neutral
Price Target:―
Synergy CHC presents a mixed outlook. While the stock is undervalued based on its P/E ratio, significant financial risks due to high leverage and liquidity issues are concerning. The company's bearish technical indicators and lack of a clear positive earnings call narrative further weigh down the score. On the positive side, corporate events such as leadership changes and strategic partnerships suggest potential future growth.
Synergy CHC (SNYR) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$30.11M
Dividend YieldN/A
Average Volume (3M)136.07K
Price to Earnings (P/E)7.2
Beta (1Y)0.72
Revenue GrowthN/A
EPS GrowthN/A
CountryUS
Employees21
SectorHealthcare
Sector Strength45
IndustryMedical - Distribution
Share Statistics
EPS (TTM)0.17
Shares Outstanding11,191,853
10 Day Avg. Volume89,526
30 Day Avg. Volume136,069
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market Cap1.69
Enterprise Value/Revenue1.51
Enterprise Value/Gross Profit2.14
Enterprise Value/Ebitda5.77
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusModerate Buy
Number of Analyst Covering0
Synergy CHC Business Overview & Revenue Model
Company DescriptionSynergy CHC Corp. (SNYR) is a consumer health care company focused on marketing and distributing a portfolio of innovative over-the-counter health and wellness products. The company's offerings span across various sectors, including dietary supplements, personal care, and beauty products. Synergy CHC is committed to providing solutions that enhance consumer well-being and improve overall quality of life.
How the Company Makes MoneySynergy CHC generates revenue primarily through the sale of its health and wellness products. The company markets and distributes these products through various retail channels, including online platforms and brick-and-mortar stores. Key revenue streams include direct sales to consumers and partnerships with retailers who stock and sell Synergy CHC's product lines. The company's earnings are significantly influenced by their marketing strategies, product innovation, and ability to establish strong brand recognition in the competitive consumer health care market.
Synergy CHC Earnings Call Summary
Earnings Call Date:Aug 14, 2025
(Q3-2024)
| % Change Since: |
Next Earnings Date:Nov 13, 2025
Earnings Call Sentiment Neutral
The earnings call reflected a challenging quarter primarily due to a strategic rebranding and de-inventorying process that impacted revenues. However, the company achieved significant milestones, including a successful IPO and expansion into new retail channels, indicating potential for future growth.Q3-2024 Updates
Positive Updates
Successful IPO Completion
Synergy completed its IPO in late October, raising approximately $6.2 million in net proceeds and began trading on the Nasdaq under the symbol SNYR.
Seven Consecutive Quarters of Profitability
Synergy reported its seventh consecutive quarter of profitable results, marking continued financial stability.
Expansion into New Retail Channels
Synergy expanded its retail relationships with BJ's Wholesale Clubs and Publix, increasing distribution points across key markets.
Global Trademark Strategy
Synergy registered 22 FOCUSfactor trademarks globally, paving the way for future growth and sustained market leadership.
Negative Updates
Significant Revenue Decline
Revenue in the third quarter was $7.1 million compared to $10.8 million in the year-ago quarter, a decrease of 34%, primarily due to rebranding and retailer de-inventorying.
Gross Margin Reduction
Gross margin in the third quarter decreased 476 basis points to 67.2% compared to 72% a year ago, due to product mix sold within the quarter.
Flat Tummy Brand Revenue Decline
Flat Tummy brand revenue was not up year-over-year, following a sell-through of previous products and prior to the launch of new SKUs.
CFO Departure
CFO Stacy Bieber announced her departure to pursue new opportunities, with Jaime Fickett stepping in as Interim CFO.
Company Guidance
During Synergy CHC Corporation's Q3 2024 earnings call, several key metrics and strategic initiatives were discussed. The company reported a revenue decline to $7.1 million, down from $10.8 million in Q3 2023, attributed primarily to a rebranding effort for their FOCUSfactor products, which led to a temporary $3 million sales impact due to retailer de-inventorying. Despite this, the company maintained a gross margin of 67.2%. EBITDA was reported at $1.3 million, marking a 38% decrease from the previous year. Synergy also highlighted its strategic expansion, noting new retail partnerships, including placement in all 267 BJ's Wholesale Clubs and all 1,200 Publix grocery stores. The company is poised for future growth with plans to introduce new product SKUs and expand its ready-to-drink beverage line in early 2025. The recent IPO, which raised $6.2 million in net proceeds, allowed Synergy to reduce its debt by $3.1 million, strengthening its financial position.Synergy CHC Financial Statement Overview
Summary
Synergy CHC shows revenue growth, but profitability is inconsistent, with significant financial instability due to high leverage and negative equity. Cash flow struggles further highlight liquidity issues, despite some operational efficiencies.Income Statement
Synergy CHC shows a mixed income statement performance with a significant increase in total revenue from 2023 to 2024. However, the net profit margin remains low and inconsistent over the years, highlighting challenges in achieving sustained profitability. The EBIT and EBITDA margins are positive, indicating some operational efficiencies, yet net income remains volatile.45
Neutral
Balance Sheet
The company's balance sheet indicates high leverage with a significant debt-to-equity ratio due to negative equity, which poses financial risks. ROE is not meaningful due to negative equity, and the equity ratio is also negative. These factors suggest financial instability and potential challenges in meeting long-term obligations.30
Negative
Cash Flow
Cash flow analysis reveals negative operating and free cash flows in recent years, reflecting liquidity struggles. The operating cash flow to net income ratio is concerning, indicating difficulty in translating profits into cash. Despite these challenges, financing activities have been positive, suggesting reliance on external funding.40
Negative
| Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 33.70M | 34.83M | 42.78M | 38.41M | 0.00 | 40.23M |
| Gross Profit | 23.69M | 23.64M | 32.08M | 13.30M | 0.00 | 25.55M |
| EBITDA | 8.80M | 6.47M | 10.84M | -24.63M | 0.00 | 2.81M |
| Net Income | 3.24M | 2.12M | 6.34M | -32.63M | 0.00 | 1.41M |
Balance Sheet | ||||||
| Total Assets | 19.73M | 16.34M | 12.24M | 18.54M | 0.00 | 12.59M |
| Cash, Cash Equivalents and Short-Term Investments | 1.46M | 687.92K | 632.53K | 1.93M | 0.00 | 1.67M |
| Total Debt | 26.87M | 27.52M | 27.63M | 22.83M | 0.00 | 8.75M |
| Total Liabilities | 32.11M | 32.97M | 39.55M | 52.06M | 0.00 | 16.27M |
| Stockholders Equity | -12.38M | -16.63M | -27.31M | -33.52M | 0.00 | -3.68M |
Cash Flow | ||||||
| Free Cash Flow | -4.85M | -4.80M | 421.73K | -8.43M | 0.00 | -1.59M |
| Operating Cash Flow | -4.85M | -4.80M | 421.73K | -8.43M | 0.00 | -1.59M |
| Investing Cash Flow | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | -361.39K |
| Financing Cash Flow | 5.43M | 4.80M | -2.09M | 8.96M | 0.00 | 1.95M |
Synergy CHC Technical Analysis
Positive
2.69
Price Trends
2.54
Positive
2.77
Negative
2.89
Negative
Market Momentum
<0.01
Negative
57.21
Neutral
57.49
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SNYR, the sentiment is Positive. The current price of 2.69 is above the 20-day moving average (MA) of 2.44, above the 50-day MA of 2.54, and below the 200-day MA of 2.89, indicating a neutral trend. The MACD of <0.01 indicates Negative momentum. The RSI at 57.21 is Neutral, neither overbought nor oversold. The STOCH value of 57.49 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for SNYR.
Synergy CHC Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
54 Neutral | $10.60M | -1.73 | -6.45% | ― | -22.37% | 63.14% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
51 Neutral | $71.91M | 7.99 | 19.38% | ― | -8.51% | ― | |
48 Neutral | $381.59M | ― | -144.11% | ― | -17.10% | -2720.40% | |
47 Neutral | $30.11M | 7.24 | ― | ― | ― | ― | |
44 Neutral | $41.36M | ― | -168.22% | ― | -25.21% | -631.48% |
* Healthcare Sector Average
SNYR
Synergy CHC
2.69
-6.32
-70.14%
RDGT
Ridgetech
1.71
-0.13
-7.07%
OMI
Owens & Minor
5.31
-8.37
-61.18%
GEG
Great Elm Group
2.45
0.66
36.87%
ZYXI
Zynex
1.34
-7.25
-84.40%
WGRX
Wellgistics Health Inc
0.37
-2.66
-87.79%
Synergy CHC Corporate Events
Executive/Board ChangesBusiness Operations and StrategyFinancial Disclosures
Synergy CHC Appoints New CFO Amidst Leadership Changes
Positive
Mar 31, 2025
On March 27, 2025, Synergy CHC appointed Jaime Fickett as the new Chief Financial Officer, marking a significant leadership change. The company reported its eighth consecutive quarter of profitability for 2024, despite a decrease in revenue and net income due to rebranding efforts and retailer de-inventorying. Synergy successfully completed its initial public offering in October 2024 and expanded its partnerships with major retailers, positioning itself for future growth.
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.